SWI/SNF protein expression status in fumarate hydratase-deficient renal cell carcinoma: immunohistochemical analysis of 32 tumors from 28 patients
Language English Country United States Media print-electronic
Document type Journal Article
PubMed
29689242
DOI
10.1016/j.humpath.2018.04.004
PII: S0046-8177(18)30124-2
Knihovny.cz E-resources
- Keywords
- ARID1A, Fumarate hydratase, HLRCC, INI1, Renal cell carcinoma, SMARCB1, SWI/SNF complex,
- MeSH
- Chromosomal Proteins, Non-Histone metabolism MeSH
- DNA-Binding Proteins MeSH
- DNA Helicases genetics metabolism MeSH
- Adult MeSH
- Fumarate Hydratase deficiency MeSH
- Immunohistochemistry methods MeSH
- Nuclear Proteins genetics metabolism MeSH
- Carcinoma, Renal Cell genetics pathology MeSH
- Middle Aged MeSH
- Humans MeSH
- Adolescent MeSH
- Young Adult MeSH
- Mutation genetics MeSH
- Kidney Neoplasms genetics pathology MeSH
- Aged MeSH
- Transcription Factors genetics metabolism MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Adolescent MeSH
- Young Adult MeSH
- Male MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Names of Substances
- Chromosomal Proteins, Non-Histone MeSH
- DNA-Binding Proteins MeSH
- DNA Helicases MeSH
- Fumarate Hydratase MeSH
- Nuclear Proteins MeSH
- PBRM1 protein, human MeSH Browser
- SMARCA2 protein, human MeSH Browser
- SMARCA4 protein, human MeSH Browser
- SMARCC1 protein, human MeSH Browser
- SMARCC2 protein, human MeSH Browser
- Transcription Factors MeSH
Fumarate hydratase-deficient renal cell carcinoma (FH-RCC) is a rare, aggressive RCC type, originally described in the setting of hereditary leiomyomatosis and RCC syndrome, which is defined by germline FH gene inactivation. Inactivation of components of the switch/sucrose nonfermentable (SWI/SNF) chromatin remodeling complex is involved in renal medullary carcinoma (SMARCB1/INI1 loss), clear cell RCC (PBRM1 loss), and subsets of dedifferentiated RCC of clear cell, chromophobe, and papillary types (loss of different SWI/SNF components). FH-RCC and SWI/SNF-deficient RCC share anaplastic nuclear features and highly aggressive course. We analyzed 32 FH-RCCs from 28 patients using 7 commercially available SWI/SNF antibodies (SMARCB1/INI1, SMARCA2, SMARCA4, SMARCC1, SMARCC2, PBRM1, and ARID1A). Variable loss of SMARCB1, ARID1A, and SMARCC1 was observed in 1 of 31, 2 of 31, and 1 of 29 evaluable cases, respectively; 3 of these 4 SWI/SNF-deficient tumors had confirmed FH mutations. No correlation of SWI/SNF loss with solid or sarcomatoid features was observed. Two tumors with SMARCB1 and ARID1A deficiency had available SWI/SNF molecular data; both lacked SMARCB1 and ARID1A mutations. The remaining 5 SWI/SNF components were intact in all cases. Especially PBRM1 seems not to be involved in the pathogenesis or progression of FH-RCC. Our data showed that a subset of FH-RCC (12%) have a variable loss of SWI/SNF complex subunits, likely as secondary genetic events. This should not be confused with SWI/SNF-deficient RCC of other types. Evaluation of FH and SWI/SNF together with comprehensive molecular genetic profiling is needed to explore possible prognostic implications of FH/SWI-SNF double deficiency and to better understand the somatic mutation landscape in high-grade RCC.
Barts Cancer Institute Queen Mary University of London London ECIM 6BQ UK
Calgary Laboratory Services and University of Calgary Calgary Alberta Canada
Charles University and University Hospital Plzen 304 60 Plzen Czech Republic
Cleveland Clinic Cleveland OH 44195 USA
Department of Pathology VCU School of Medicine Richmond VA 23298 USA
Hospital Cochin 75679 Paris France
Institute of Human Genetics Friedrich Alexander University Erlangen Nürnberg Erlangen Germany
References provided by Crossref.org